NEW DELHI: With an intention to release vaccine for Influenza H1N1 A Virus (swine flu) in India, Cadila Pharmaceutical will seek the federal government's nod in two days for beginning medical trials in this regard.
Cadila Pharmaceutical Ltd (CPL) had arrange a joint venture 'CPL Biologicals Pvt Ltd' with the US-based vaccine maker Novavax for manufacturing and creating a bunch of vaccines, together with for swine flu, in India.
"The joint venture is going to file the application with the Drug Controller General of India (DCGI) in the next two days for phase-I clinical trials for swine flu vaccine," CPL Chairman and Managing Director I A Modi stated.
Modi expressed self belief that Cadila would be the first Indian pharma company to release the swine flu vaccine in India via December.
"If we get the permission of DCGI soon, then with the advanced technology available from our partner, (we) would be able to launch it in India by December this year," Modi stated.
With its current facility, Cipla can produce as much as a million doses of the vaccine per 30 days, which can be scaled as much as two million doses, Modi stated.
"Novavax has already received permission for clinical trials from the US Federal Drug Administration and if we get it soon, we can simultaneously start the trials," he added.
The executive has already indicated that swine flu similar applications it would transparent on a fast monitor basis and the corporate is hopeful of having rapid popularity of it, Modi added.
He stated to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks.
The JV has already started construction a facility with an estimated funding of Rs 100 crore. In the joint venture Cadila has 80 according to cent stake and the rest 20 according to cent is held via Novavax.
Besides this, Cadila Pharma additionally holds five.75 according to cent stake in Novavax Inc US and has a place on the board of administrators of the US-based company.
Cadila Pharmaceutical Ltd (CPL) had arrange a joint venture 'CPL Biologicals Pvt Ltd' with the US-based vaccine maker Novavax for manufacturing and creating a bunch of vaccines, together with for swine flu, in India.
"The joint venture is going to file the application with the Drug Controller General of India (DCGI) in the next two days for phase-I clinical trials for swine flu vaccine," CPL Chairman and Managing Director I A Modi stated.
Modi expressed self belief that Cadila would be the first Indian pharma company to release the swine flu vaccine in India via December.
"If we get the permission of DCGI soon, then with the advanced technology available from our partner, (we) would be able to launch it in India by December this year," Modi stated.
With its current facility, Cipla can produce as much as a million doses of the vaccine per 30 days, which can be scaled as much as two million doses, Modi stated.
"Novavax has already received permission for clinical trials from the US Federal Drug Administration and if we get it soon, we can simultaneously start the trials," he added.
The executive has already indicated that swine flu similar applications it would transparent on a fast monitor basis and the corporate is hopeful of having rapid popularity of it, Modi added.
He stated to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks.
The JV has already started construction a facility with an estimated funding of Rs 100 crore. In the joint venture Cadila has 80 according to cent stake and the rest 20 according to cent is held via Novavax.
Besides this, Cadila Pharma additionally holds five.75 according to cent stake in Novavax Inc US and has a place on the board of administrators of the US-based company.
Cadila to apply for clinical trials for swine flu vaccine
![Cadila to apply for clinical trials for swine flu vaccine]()
Reviewed by Kailash
on
January 21, 2018
Rating:
